ARTICLE | Clinical News
Interleukin-2 (IL-2) gene therapy: Completed Phase IIb trial
February 20, 2001 8:00 AM UTC
Valentis Inc. (VLTS), Burlingame, Calif. Product: Interleukin-2 (IL-2) gene therapy Business: Cancer, Gene/Cell therapy Therapeutic category: Gene therapy, Immune stimulation Target: Tumor cells Desc...